FTC approves final action related to false Hepaxa claims
FTC approves final action related to false Hepaxa claims BASF, U.S. distributor made deceptive claims about the supplement’s ability to reduce liver fat in people with non-alcoholic fatty liver disease (NAFLD) Federal regulators have approved final administrative consent orders against three companies, including global chemical giant BASF SE, which will settle charges that the companies deceptively marketed two dietary fish oil supplements as clinically proven to reduce liver fat in adults and children with non-alcoholic fatty liver disease (NAFLD). BASF’s Hepaxa and Hepaxa PD suppl...
Source: naturalproductsinsider.com